Login to Your Account

Cell Therapeutics' Pacritinib Phase III Program Takes Off

By Catherine Shaffer
Staff Writer

Wednesday, January 9, 2013
Cell Therapeutics Inc., of Seattle, began a much-anticipated Phase III trial for its JAK2 inhibitor, pacritinib, in myelofibrosis. It licensed the drug from Singapore-based S*Bio Pte Ltd. in April for $30 million up front and up to $132.5 million in regulatory and sales milestones.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription